HeartBeam (NASDAQ: BEAT) has announced the launch of a pilot study focused on testing its proprietary on-demand 12-lead ECG patch for detecting coronary artery disease and ischemia—a condition involving inadequate blood flow and oxygen supply to tissue. The study marks a significant step in the development of the HeartBeam patch, which aims to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (MCT) markets.
Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of deaths each year and often progressing silently until a major cardiac event occurs. As healthcare providers search for faster and more accessible ways to identify high-risk patients earlier, HeartBeam’s technology could offer a new solution. The patch is designed to provide clinical-grade insights over an extended period, a capability not currently available on patch-based ambulatory monitors.
“Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time,” said HeartBeam CEO Robert Eno. “The HeartBeam patch is designed to change that. A device capable of generating an on-demand 12-lead ECG could enable earlier detection of coronary artery disease, potentially reducing the risk of major cardiac events.”
The study represents a pivotal moment for HeartBeam as it seeks to validate its technology in a clinical setting. If successful, the patch could provide a non-invasive, accessible tool for continuous monitoring, allowing patients to record ECGs on-demand when symptoms arise. This could be particularly valuable for patients with intermittent symptoms that are not captured during standard short-term monitoring.
The potential impact on the healthcare industry is substantial. The long-term continuous monitor and MCT markets are dominated by devices that track heart rhythm but lack the ability to detect ischemia. HeartBeam’s patch could fill this gap, offering a more comprehensive monitoring solution. For patients, this means the possibility of earlier diagnosis and intervention, which could improve outcomes and reduce healthcare costs associated with advanced coronary artery disease.
HeartBeam’s announcement comes as the seriousness of coronary artery disease continues to intensify with aging populations and increasing cardiovascular risk factors. The company’s focus on developing a patch that can generate a standard 12-lead ECG on demand addresses a critical unmet need in ambulatory monitoring.
For more information on HeartBeam and the latest updates, visit the company’s newsroom at https://ibn.fm/BEAT. Full terms of use and disclaimers are available at http://IBN.fm/Disclaimer.
